Insurance and Incentives for Medical Innovation
30 Pages Posted: 11 May 2006 Last revised: 6 Jul 2022
Date Written: March 2006
Abstract
This paper studies the interactions between health insurance and the incentives for innovation. Although we focus on pharmaceutical innovation, our discussion applies to other industries producing novel technologies for sale in markets with subsidized demand. Standard results in the growth and productivity literatures suggest that firms in many industries may possess inadequate incentives to innovate. Standard results in the health literature suggest that health insurance leads to the overutilization of health care. Our study of innovation in the pharmaceutical industry emphasizes the interaction of these incentives. Because of the large subsidies to demand from health insurance, limits on the lifetime of patents and possibly limits on monopoly pricing may be necessary to ensure that pharmaceutical companies do not possess excess incentives for innovation.
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Accounting for Future Costs in Medical Cost-Effectiveness Analysis
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments
By Mark Duggan and William N. Evans
-
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets
-
By Tomas Philipson and Anupam B. Jena
-
Advances in Cost-Effectiveness Analysis of Health Interventions
-
The Welfare Effects of Public Drug Insurance
By Darius N. Lakdawalla and Neeraj Sood
-
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
By Tomas Philipson and Anupam B. Jena